A detailed history of Advisor Group Holdings, Inc. transactions in Inmune Bio, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 12,270 shares of INMB stock, worth $99,018. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,270
Previous 10,700 14.67%
Holding current value
$99,018
Previous $120,000 20.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$10.53 - $14.01 $16,532 - $21,995
1,570 Added 14.67%
12,270 $144,000
Q4 2023

Feb 12, 2024

BUY
$6.6 - $11.52 $14,520 - $25,344
2,200 Added 25.88%
10,700 $120,000
Q3 2023

Nov 13, 2023

SELL
$6.61 - $10.9 $17,847 - $29,430
-2,700 Reduced 24.11%
8,500 $57,000
Q2 2023

Aug 10, 2023

BUY
$6.5 - $10.09 $21,222 - $32,943
3,265 Added 41.15%
11,200 $101,000
Q1 2023

May 12, 2023

SELL
$6.01 - $10.18 $7,903 - $13,386
-1,315 Reduced 14.22%
7,935 $51,000
Q4 2022

Feb 10, 2023

BUY
$6.31 - $7.96 $20,192 - $25,472
3,200 Added 52.89%
9,250 $58,000
Q3 2022

Nov 14, 2022

BUY
$6.91 - $10.44 $3,406 - $5,146
493 Added 8.87%
6,050 $38,000
Q2 2022

Aug 10, 2022

SELL
$5.48 - $8.97 $150,935 - $247,060
-27,543 Reduced 83.21%
5,557 $49,000
Q1 2022

May 04, 2022

BUY
$6.42 - $11.39 $134,370 - $238,392
20,930 Added 171.98%
33,100 $279,000
Q3 2021

Nov 05, 2021

SELL
$14.13 - $27.85 $213,249 - $420,312
-15,092 Reduced 55.36%
12,170 $237,000
Q2 2021

Aug 02, 2021

BUY
$9.29 - $19.33 $179,111 - $372,682
19,280 Added 241.54%
27,262 $479,000
Q1 2021

May 13, 2021

BUY
$11.61 - $26.85 $23,011 - $53,216
1,982 Added 33.03%
7,982 $94,000
Q3 2020

Nov 12, 2020

BUY
$4.92 - $15.75 $28,536 - $91,350
5,800 Added 2900.0%
6,000 $62,000
Q2 2020

Aug 14, 2020

SELL
$3.1 - $6.09 $310 - $609
-100 Reduced 33.33%
200 $1,000
Q1 2020

May 18, 2020

BUY
$2.21 - $6.15 $663 - $1,845
300 New
300 $1,000

Others Institutions Holding INMB

About Inmune Bio, Inc.


  • Ticker INMB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,946,000
  • Market Cap $145M
  • Description
  • INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...
More about INMB
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.